CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology)

N/A

Report date: 2022/11/21 10:53:44

Base Information

Drug NameCD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19Anti-CD22

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaBurkitt Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesFederal Research Institute of Pediatric Hematology Oncology and Immunology

China Registration ClassN/A

Develop Information

Active CompaniesFederal Research Institute of Pediatric Hematology Oncology and Immunology

Inactive CompaniesN/A

Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaBurkitt Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A